CARsgen Therapeutics has selected Durham County, North Carolina for a $157 million expansion of its R&D and commercial manufacturing operation, Triangle Business Journal reported.
The company, which has clinical development operations in Houston, said it expects to invest $157 million in the operation by 2025.
The project is expected to create 200 new jobs between 2022 and 2026.
"CARsgen will continuously develop and embed innovations to advance the revolutionary CAR-T cell therapy for unmet clinical needs," said CEO Zonghai Li.
"The company has launched clinical studies of our leading CT053 and CT041 CAR-T cell therapies in the US," Li said, adding that "The new facilities will expand our global cGMP manufacturing capacity to produce the innovative CAR-T cell products for the US patients."
To read more NewsPoints articles, click here.